The plan – which is due to be operational in 2019 – will make a range of amines including 1,2-Propylenediamine (1,2-PDA), which is used as a building block in the manufacture of a wide range of active pharmaceutical ingredients (API).
Narayan Krishnamohan, senior VP of BASF’s intermediates business in Asia Pacific, said: “This investment will help us to meet the increasing Asia Pacific demand for specialty amines used as intermediates in a diverse range of industries and applications.”